|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
WO1993021319A1
(en)
|
1992-04-08 |
1993-10-28 |
Cetus Oncology Corporation |
HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
CA2376596C
(en)
|
1999-06-25 |
2009-10-06 |
Genentech, Inc. |
Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
TR200200472T2
(tr)
|
1999-08-27 |
2002-06-21 |
Genentech, Inc. |
Anti-Erb B2 antikorları ile tedavi için dozajlar
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
CN100427603C
(zh)
|
1999-10-04 |
2008-10-22 |
麦迪卡格公司 |
调控外源基因转录的方法
|
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
|
AU2002241922B2
(en)
|
2001-01-17 |
2007-10-25 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
ES2533963T3
(es)
|
2002-10-10 |
2015-04-16 |
Merck Patent Gmbh |
Composiciones farmacéuticas dirigidas a receptores Erb-B1
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
KR20140032004A
(ko)
|
2004-07-22 |
2014-03-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
CA2592177A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
|
CA2602663A1
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
WO2008031531A1
(en)
*
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Tumor therapy with a combination of anti-her2 antibodies
|
|
EP2220120A2
(en)
|
2007-11-27 |
2010-08-25 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
CA2711256C
(en)
|
2008-01-03 |
2019-01-15 |
The Scripps Research Institute |
Antibody targeting through a modular recognition domain
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
BRPI1010620B8
(pt)
|
2009-06-03 |
2021-05-25 |
Immunogen Inc |
métodos de conjugação
|
|
ES2688978T3
(es)
|
2009-11-23 |
2018-11-07 |
Amgen Inc. |
Anticuerpo monomérico Fc
|
|
ES2751549T3
(es)
|
2009-11-30 |
2020-04-01 |
Janssen Biotech Inc |
Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
BR112012024489A2
(pt)
|
2010-03-29 |
2016-05-31 |
Zymeworks Inc |
anticorpos com função efetora suprimida ou aumentada
|
|
WO2011135040A1
(en)
|
2010-04-30 |
2011-11-03 |
F. Hoffmann-La Roche Ag |
Fluorescent antibody fusion protein, its production and use
|
|
CN114805583A
(zh)
|
2010-05-27 |
2022-07-29 |
根马布股份公司 |
针对her2的单克隆抗体
|
|
JP6082344B2
(ja)
|
2010-05-27 |
2017-02-15 |
ゲンマブ エー／エス |
Ｈｅｒ２エピトープに対するモノクローナル抗体
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
US9683052B2
(en)
*
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
US20130216523A1
(en)
|
2011-03-31 |
2013-08-22 |
Laboratory Corporation Of America Holdings |
Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
|
|
JP6177231B2
(ja)
*
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
CN107266577B
(zh)
*
|
2011-10-11 |
2022-09-13 |
弗·哈夫曼-拉罗切有限公司 |
双特异性抗体的改进的组装
|
|
CA2854233C
(en)
*
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
NZ629283A
(en)
|
2012-03-16 |
2016-04-29 |
Covagen Ag |
Novel binding molecules with antitumoral activity
|
|
US20150125449A1
(en)
|
2012-05-10 |
2015-05-07 |
Zymeworks Inc. |
Single-Arm Monovalent Antibody Constructs and Uses Thereof
|
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
CA2883264A1
(en)
|
2012-10-15 |
2014-04-24 |
Universitat Zurich Prorektorat Mnw |
Bispecific her2 ligands for cancer therapy
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
WO2014190441A1
(en)
|
2013-05-31 |
2014-12-04 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
HRP20250551T1
(hr)
*
|
2013-11-27 |
2025-06-20 |
Zymeworks Bc Inc. |
Bispecifični antigen-vezujući konstrukti koji ciljaju her2
|
|
EP3327038B1
(en)
|
2013-12-20 |
2020-09-23 |
F. Hoffmann-La Roche AG |
Bispecific her2 antibodies and methods of use
|
|
EP3223848B1
(en)
|
2014-11-27 |
2024-11-27 |
Zymeworks BC Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
US11028182B2
(en)
|
2015-05-13 |
2021-06-08 |
Zymeworks Inc. |
Antigen-binding constructs targeting HER2
|
|
ES2958933T3
(es)
*
|
2018-03-13 |
2024-02-16 |
Zymeworks Bc Inc |
Conjugados de anticuerpo biparatópico anti-HER2-fármaco y métodos de uso
|